No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorKafrelsheikh University
About this trial
This study aims to assess the no-reflow in patients with STEMI after intracoronary glycoprotein IIb/IIIa inhibitors after opening of track in thrombus.
Eligibility criteria
Qualifiers
Age ≥ 18 years old.
Both sexes.
Patients with STEMI. ST-segment elevated myocardial infarction is defined as typical chest pain >30 minutes with ST-segment elevation of >1 mm in at least 2 consecutive leads on the electrocardiogram or new-onset left bundle brunch block.
Disqualifiers
Treatment with thrombolytic drugs in the previous 24 hours.
Known malignancy.
Thrombocytopenia.
End-stage liver disease.
Trial design
Treatments tested in this trial
- Intracoronary tirofiban
- Saline 0.9%
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov